4.94
price down icon4.82%   -0.25
after-market アフターアワーズ: 5.25 0.31 +6.28%
loading
前日終値:
$5.19
開ける:
$5.09
24時間の取引高:
2.40M
Relative Volume:
1.79
時価総額:
$682.91M
収益:
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.2602
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+9.78%
1か月 パフォーマンス:
-17.39%
6か月 パフォーマンス:
-37.94%
1年 パフォーマンス:
-52.45%
1日の値動き範囲:
Value
$4.72
$5.09
1週間の範囲:
Value
$4.44
$5.24
52週間の値動き範囲:
Value
$4.32
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
名前
Vir Biotechnology Inc
Name
セクター
Healthcare (1170)
Name
電話
415-906-4324
Name
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Name
職員
408
Name
Twitter
@Vir_Biotech
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
VIR's Discussions on Twitter

VIR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VIR
Vir Biotechnology Inc
4.94 622.07M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-29 ダウングレード JP Morgan Overweight → Neutral
2023-09-08 ダウングレード BofA Securities Buy → Neutral
2023-03-06 アップグレード JP Morgan Neutral → Overweight
2023-02-21 アップグレード Goldman Neutral → Buy
2023-01-27 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-09-14 開始されました SVB Leerink Outperform
2022-09-09 開始されました Morgan Stanley Underweight
2022-03-03 アップグレード Robert W. Baird Underperform → Neutral
2021-12-21 ダウングレード Robert W. Baird Neutral → Underperform
2021-10-25 アップグレード JP Morgan Underweight → Neutral
2021-09-22 ダウングレード Goldman Buy → Neutral
2021-06-04 再開されました Robert W. Baird Neutral
2021-01-27 ダウングレード JP Morgan Neutral → Underweight
2021-01-20 繰り返されました H.C. Wainwright Buy
2020-10-05 開始されました BofA Securities Buy
2020-09-14 アップグレード Goldman Neutral → Buy
2020-09-11 アップグレード JP Morgan Underweight → Neutral
2020-08-20 開始されました Needham Buy
2020-03-19 ダウングレード JP Morgan Neutral → Underweight
2020-03-13 ダウングレード Goldman Buy → Neutral
2020-02-27 ダウングレード Robert W. Baird Neutral → Underperform
2020-02-04 ダウングレード JP Morgan Overweight → Neutral
2019-11-14 開始されました Robert W. Baird Neutral
2019-11-05 開始されました Barclays Overweight
2019-11-05 開始されました Cowen Outperform
2019-11-05 開始されました Goldman Buy
2019-11-05 開始されました JP Morgan Overweight
すべてを表示

Vir Biotechnology Inc (VIR) 最新ニュース

pulisher
May 29, 2025

Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace

May 29, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus

May 28, 2025
pulisher
May 22, 2025

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 22, 2025
pulisher
May 22, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace

May 21, 2025
pulisher
May 20, 2025

Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025
pulisher
May 15, 2025

How To Trade (VIR) - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

May 15, 2025
pulisher
May 14, 2025

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

May 14, 2025
pulisher
May 12, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace

May 12, 2025
pulisher
May 12, 2025

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

May 12, 2025
pulisher
May 11, 2025

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace

May 08, 2025
pulisher
May 07, 2025

Vir Biotechnology Q1 2025 Earnings Call Transcript - MarketBeat

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com India

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clin - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology Q1 2025 Earnings Preview - MSN

May 07, 2025

Vir Biotechnology Inc (VIR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):